Alzheimer's disease: Time to focus on the brain, not just molecules

Brain

Volumn 140, Issue 2, 2017, Pages 251-253

  Husain, Masud ^a  

^a Oxford   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SOLANEZUMAB; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; BRAIN DEGENERATION; BRAIN FUNCTION; COGNITIVE DEFECT; EDITORIAL; HUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; APATHY; BRAIN; DISEASE EXACERBATION; EARLY INTERVENTION; EPISODIC MEMORY; EXECUTIVE FUNCTION; MEMORY DISORDER; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHENOTYPE; PSYCHOLOGY; RESEARCH; SPATIAL BEHAVIOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; APATHY; BRAIN; DISEASE PROGRESSION; EARLY MEDICAL INTERVENTION; EXECUTIVE FUNCTION; HUMANS; MEMORY DISORDERS; MEMORY, EPISODIC; MOLECULAR TARGETED THERAPY; PHENOTYPE; RESEARCH; SPATIAL PROCESSING; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85014761417     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww353     Document Type: Editorial

References (17)

1. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663-72.
2. Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain 2015; 138: 2814-33.
3. Brosch JR, Farlow MR, Risacher SL, Apostolova LG. Tau imaging in Alzheimer's disease diagnosis and clinical trials. Neurotherapeutics 2016 Nov 21. [Epub ahead of print].
4. Canter RG, Penney J, Tsai L-H. The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature 2016; 539: 187-96.
5. Godyń J, Jończyk J, Panek D, Malawska B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol Rep 2016; 68: 127-38.
6. Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 2017; 140: 266-278.
7. Liang Y, Pertzov Y, Nicholas JM, Henley SMD, Crutch S, Woodward F, et al. Visual short-term memory binding deficit in familial Alzheimer's disease. Cortex 2016; 78: 150-64.
8. Mirzadeh Z, Bari A, Lozano AM. The rationale for deep brain stimulation in Alzheimer's disease. J. Neural Transm 2016; 123: 775-83.
9. Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci 2016; 17: 777-92.
10. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-54.
11. Rolinski M, Zokaei N, Baig F, Giehl K, Quinnell T, Zaiwalla Z, et al. Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease. Brain 2016; 139: 47-53.
12. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012; 109: E2895-903.
13. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 2016; 8: 595-608.
14. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Ab plaques in Alzheimer's disease. Nature 2016; 537: 50-6.
15. Thal DR, Vandenberghe R. Monitoring the progression of Alzheimer's disease with τ-PET. Brain 2016; 139: 1318-20.
16. Villemagne VL. Amyloid imaging: Past, present and future perspectives. Ageing Res Rev 2016; 30: 95-106.
17. Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, et al. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol 2016; 80: 858-70.